- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Gastro-oesophageal cancer
- Meeting Date:
Tislelizumab – July 2026
- Solution concentrate for I.V. infusion 100 mg in 10 ml
- Solution concentrate for I.V. infusion 150 mg in 15 ml
Last updated
13 November 2026
